Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Long-term Survivors after Chemotherapy in Advanced Non-small Cell Lung Cancer

HIROAKI SATOH, HIROICHI ISHIKAWA, GEN OHARA, KATSUNORI KAGOHASHI, KOICHI KURISHIMA, MORIO OHTSUKA and NOBUYUKI HIZAWA
Anticancer Research November 2007, 27 (6C) 4457-4460;
HIROAKI SATOH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hirosato@md.tsukuba.ac.jp
HIROICHI ISHIKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEN OHARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUNORI KAGOHASHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI KURISHIMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MORIO OHTSUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUYUKI HIZAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Chemotherapy is considered to have a marginal impact on survival. The purpose of this study was to evaluate the rate of long-term survival in patients treated with chemotherapy for advanced non-small cell lung cancer (NSCLC). Patients and Methods: The case records of 109 patients with NSCLC treated with chemotherapy from March 1998 to March 2007 were reviewed. Results: Fourteen (12.8%) and seven (6.4%) patients survived for more than two or three years, respectively. All of the 14 patients had performance status (PS) 0 or 1, and they were given a platinum-containing chemotherapy as initial treatment. By means of univariate analysis, good PS and gefitinib therapy were proved to be good prognostic factors. With Cox's model analysis, these two variables were confirmed as significant determinants of survival. Conclusion: A small but definite proportion of patients with locally-advanced and metastatic NSCLC might potentially survive for more than 2 years with appropriate chemotherapy.

  • Non-small cell lung cancer
  • chemotherapy
  • long-term survival
  • gefitinib

Footnotes

  • Received July 2, 2007.
  • Revision received October 2, 2007.
  • Accepted October 8, 2007.
  • Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 27 (6C)
Anticancer Research
Vol. 27, Issue 6C
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term Survivors after Chemotherapy in Advanced Non-small Cell Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Long-term Survivors after Chemotherapy in Advanced Non-small Cell Lung Cancer
HIROAKI SATOH, HIROICHI ISHIKAWA, GEN OHARA, KATSUNORI KAGOHASHI, KOICHI KURISHIMA, MORIO OHTSUKA, NOBUYUKI HIZAWA
Anticancer Research Nov 2007, 27 (6C) 4457-4460;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Long-term Survivors after Chemotherapy in Advanced Non-small Cell Lung Cancer
HIROAKI SATOH, HIROICHI ISHIKAWA, GEN OHARA, KATSUNORI KAGOHASHI, KOICHI KURISHIMA, MORIO OHTSUKA, NOBUYUKI HIZAWA
Anticancer Research Nov 2007, 27 (6C) 4457-4460;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling
  • Full-dose Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multi-center Phase II Study
  • Optimal Cutoff Points of CYFRA21-1 for Survival Prediction in Non-small Cell Lung Cancer Patients Based on Running Statistical Analysis
  • Google Scholar

More in this TOC Section

  • Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
  • End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
  • Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire